Surovatamig for treating relapsed or refractory B-cell acute lymphoblastic leukaemia after 2 or more lines of treatment in people 12 years and over [ID6630]

  • Awaiting development
  • GID-TA11837
  • Expected publication date: TBC

Documents

Documents created during the development process.

Notes